Scholar Rock's SMA Drug Approval

First FDA-approved treatment for spinal muscular atrophy muscle loss

Scholar Rock has received FDA approval for the first drug targeting muscle loss in spinal muscular atrophy (SMA). This treatment improves motor function in children with SMA, extending life and mobility for a condition that was previously untreatable.

For children with SMA, this represents a critical advance in addressing a condition that historically had no effective treatments. The approval marks a step toward reducing the life-limiting effects of SMA through early intervention.

Source material is unavailable, so specific impact scales and patient numbers remain with the original reporting.

Source: STAT